UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark one

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~October~~January 31, ~~2020~~2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number 001-09974

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

New York		13-2866202
(State or Other Jurisdiction of		(IRS. Employer
Incorporation or Organization)		Identification No.)

527 Madison Ave, New York, New York		10022
(Address of Principal Executive office)		(Zip Code)

212-583-0100

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock $0.01 par		ENZ		New York Stock Exchange

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated ~~filer,”~~filer”, “accelerated ~~filer,”~~filer”, “smaller reporting ~~company,”~~company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐			Accelerated filer ☐
Non-accelerated filer ☒			Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes ☐ No ☒

As of ~~December 1, 2020,~~March 8, 2021, the Registrant had ~~47,895,050~~48,228,567 shares of common stock outstanding.

ENZO BIOCHEM, INC.
FORM 10-Q
~~October~~January 31, ~~2020~~2021

INDEX

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements	13

	Consolidated Balance Sheets – ~~October~~January 31, ~~2020~~2021 (unaudited) and July 31, 2020	13

	Consolidated Statements of Operations for the three and six months ended ~~October~~January 31, 2021 and 2020 ~~and 2019~~ (unaudited)	24

	Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019~~2020 (unaudited)	35

	Consolidated Statement of Stockholders’ Equity for the three and six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019~~2020 (unaudited)	46

	Consolidated Statements of Cash Flows for the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 and ~~2029~~2020 (unaudited)	57

	Notes to the Consolidated Financial Statements	69

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1923

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2834

Item 4.	Controls and Procedures	2935

Part II – OTHER INFORMATION

Item 1.	Legal Proceedings	3036

Item 1A.	Risk Factors	3036

Item 6.	Exhibits	3036

Signatures		3137

Part 1 Financial Information

Item 1 Financial Statements

ENZO BIOCHEM, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

	October 31, 2020 (unaudited)			July 31, 2020
							January 31, 2021
ASSETS							(unaudited)			July 31,2020
Current assets:
Cash and cash equivalents	$	45,914		$	47,865		$	44,536		$	47,865
Accounts receivable, net		12,051			9,141			12,095			9,141
Inventories		8,185			7,784			9,258			7,784
Prepaid expenses		4,152			3,975			3,994			3,975
Total current assets		70,302			68,765			69,883			68,765

Property, plant, and equipment, net		14,506			14,482			14,463			14,482
Right-of-use assets		19,316			19,916			18,459			19,916
Goodwill		7,452			7,452			7,452			7,452
Intangible assets, net		460			538			393			538
Other, including restricted cash of $750		1,467			1,385			1,381			1,385
Total assets	$	113,503		$	112,538		$	112,031		$	112,538

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable - trade		7,842			8,503			4,432			8,503
Accrued liabilities		14,513			12,833			14,589			12,833
Current portion of operating lease liabilities		3,966			4,121			3,680			4,121
Other current liabilities and finance leases short term		287			344			248			344
Other short term debt		7,000			7,000			7,000			7,000
Total current liabilities		33,608			32,801			29,949			32,801

Other liabilities and finance leases long term		173			192			155			192
Operating lease liabilities, non-current		16,257			16,679			15,710			16,679
Long term debt - net		4,447			4,485			4,428			4,485
Total liabilities	$	54,485		$	54,157		$	50,242		$	54,157

Commitments and contingencies – see Note 12

Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding		—			—			-			-
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 47,895,050 at October 31, 2020 and July 31, 2020		479			479
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 48,227,750 at January 31, 2021 and 47,895,050 at July 31, 2020								482			479
Additional paid-in capital		334,640			334,473			335,688			334,473
Accumulated deficit		(277,953	)		(278,252	)		(275,651	)		(278,252	)
Accumulated other comprehensive income		1,852			1,681			1,270			1,681
Total stockholders’ equity		59,018			58,381			61,789			58,381

Total liabilities and stockholders’ equity	$	113,503		$	112,538		$	112,031		$	112,538

The accompanying notes are an integral part of these consolidated financial statements

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share data)

	Three Months Ended October 31,						Three Months Ended January 31,						Six Months Ended January 31,
	2020			2019			2021			2020			2021			2020
Revenues	$	28,655		$	20,207		$	31,466		$	19,384		$	60,121		$	39,591

Operating costs and expenses:
Cost of revenues		16,758			14,521			15,645			13,575			32,403			28,096
Research and development		746			1,054			806			1,065			1,552			2,119
Selling, general and administrative		10,014			11,139			11,013			10,693			21,027			21,832
Legal and related expense		640			1,696			2,292			2,060			2,932			3,756
Total operating costs and expenses		28,158			28,410			29,756			27,393			57,914			55,803

Operating income (loss)		497			(8,203	)		1,710			(8,009	)		2,207			(16,212	)

Other income (expense):
Interest, net		(51	)		237			(49	)		171			(100	)		408
Other		17			127			16			72			33			199
Foreign exchange (loss) gain		(164	)		191
Foreign exchange gain								625			79			461			270
Total other income (expense)		(198	)		(7,648	)		592			322			394			877

Income (loss) before income taxes								2,302			(7,687	)		2,601			(15,335	)
Income taxes								-			-			-			-
Net income (loss)	$	299		$	(7,648	)	$	2,302		$	(7,687	)	$	2,601		$	(15,335	)

Net income (loss) per common share:
Basic	$	0.01		$	(0.16	)	$	0.05		$	(0.16	)	$	0.05		$	(0.32	)
Diluted	$	0.01		$	(0.16	)	$	0.05		$	(0.16	)	$	0.05		$	(0.32	)

Weighted average common shares outstanding:
Basic		47,895			47,557			48,006			47,557			47,951			47,557
Diluted		47,905			47,557			48,053			47,557			47,973			47,557

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(in thousands)

	Three Months Ended October 31,					Three Months Ended January 31,						Six Months Ended January 31,
	2020		2019			2021			2020			2021			2020
Net income (loss)	$	299	$	(7,648	)	$	2,302		$	(7,687	)	$	2,601		$	(15,335	)
Other comprehensive gain (loss):
Other comprehensive loss:
Foreign currency translation adjustments		171		(271	)		(582	)		(83	)		(411	)		(354	)
Comprehensive income (loss)	$	470	$	(7,919	)	$	1,720		$	(7,770	)	$	2,190		$	(15,689	)

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Three Months Ended ~~October~~January 31, ~~2020~~2021 and ~~2019~~2020
(unaudited)
(in thousands, except share data)

Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity
Balance at July 31, 2020 47,895,050 $ 479 $ 334,473 $ (278,252 ) $ 1,681 $ 58,381
Net income for the period ended October 31, 2020 — — — 299 — 299
Share-based compensation charges — — 167 — — 167
Foreign currency translation adjustments — — — — 171 171
Balance at October 31, 2020 47,895,050 $ 479 $ 334,640 $ (277,953 ) $ 1,852 $ 59,018
Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity
Balance at October 31, 2020 47,895,050 $ 479 $ 334,640 $ (277,953 ) $ 1,852 $ 59,018
Net income for the period ended January 31, 2021 — — — 2,302 — 2,302
Share-based compensation
charges — — 176 — — 176
Issuance of common stock for bonus payments 332,700 3 872 — — 875
Foreign currency translation adjustments — — — — (582 ) (582 )
Balance at January 31, 2021 48,227,750 $ 482 $ 335,688 $ (275,651 ) $ 1,270 $ 61,789

Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity
Balance at July 31, 2019 47,556,807 $ 476 $ 332,704 $ (249,732 ) $ 2,580 $ 86,028
Net (loss) for the period ended October 31, 2019 — — — (7,648 ) — (7,648 )
Balance at October 31, 2019 47,556,807 $ 476 $ 332,923 $ (257,380 ) $ 2,309 $ 78,328
Net (loss) for the period ended January 31, 2020 -   -   -   (7,687 ) -   (7,687 )
Share-based compensation charges — — 219 — — 219 -   -   302 -   -   302
Vesting of restricted stock 811 -   -   -   -   -
Foreign currency translation adjustments — — — — (271 ) (271 ) -   -   -   -   (83 ) (83 )
Balance at October 31, 2019 47,556,807 $ 476 $ 332,923 $ (257,380 ) $ 2,309 $ 78,328
Balance at January 31, 2020 47,557,618 $ 476 $ 333,225 $ (265,067 ) $ 2,226 $ 70,860

The accompanying notes are an integral part of these consolidated financial statements

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Six Months Ended January 31, 2021 and 2020
(unaudited)
(in thousands, except share data)
Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity
Balance at July 31, 2020 47,895,050 $ 479 $ 334,473 $ (278,252 ) $ 1,681 $ 58,381
Net income for the period ended January 31, 2021 -   -   -   2,601 -   2,601
Share-based compensation charges -   -   343 -   -   343
Issuance of common stock for bonus payments 332,700 3 872 -   -   875
Foreign currency translation adjustments -   -   -   -   (411 ) (411 )
Balance at January 31, 2021 48,227,750 $ 482 $ 335,688 $ (275,651 ) $ 1,270 $ 61,789
Common Stock Shares Issued Common Stock
Amount Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total
Stockholders’ Equity
Balance at July 31, 2019 47,556,807 $ 476 $ 332,704 $ (249,732 ) $ 2,580 $ 86,028
Net (loss) for the period ended January 31, 2020 -   -   -   (15,335 ) -   (15,335 )
Share-based compensation
charges -   -   521 -   -   521
Vesting of restricted stock 811 -   -   -   -   -
Foreign currency translation adjustments -   -   -   -   (354 ) (354 )
Balance at January 31, 2020 47,557,618 $ 476 $ 333,225 $ (265,067 ) $ 2,226 $ 70,860
The accompanying notes are an integral part of these consolidated financial statements

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)

Three Months Ended
October 31, Six Months Ended
January 31,
2020 2019 2021 2020
Cash flows from operating activities:
Net income (loss) $ 299 $ (7,648 ) $ 2,601 $ (15,335 )
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment 585 579 1,144 1,142
Amortization of intangible assets 75 146 151 292
Share-based compensation charges 167 219 343 521
Accrual for share-based 401(k) employer match expense 211 207 423 413
Foreign exchange loss (gain) 152 (217 )
Foreign exchange (gain) (504 ) (319 )

Changes in operating assets and liabilities:
Accounts receivable (2,865 ) 890 (2,892 ) 1,848
Inventories (340 ) 310 (1,392 ) 368
Prepaid expenses and other assets (314 ) 517 (62 ) 98
Accounts payable – trade (658 ) 1,325 (4,062 ) 877
Accrued liabilities, other current liabilities and other liabilities 1,480 1,606 2,222 2,104
Total adjustments (1,507 ) 5,582 (4,629 ) 7,344

Net cash used in operating activities (1,208 ) (2,066 ) (2,028 ) (7,991 )

Cash flows from investing activities:
Capital expenditures (617 ) (274 ) (1,123 ) (434 )
Net cash used in investing activities (617 ) (274 ) (1,123 ) (434 )

Cash flows from financing activities:
Repayments under mortgage agreement and finance leases (113 ) (105 ) (207 ) (229 )
Cost to obtain loan — (66 )
Net cash used in financing activities (113 ) (171 ) (207 ) (229 )

Effect of exchange rate changes on cash and cash equivalents (13 ) 8 29 10

Decrease in cash and cash equivalents and restricted cash (1,951 ) (2,503 ) (3,329 ) (8,644 )
Cash and cash equivalents and restricted cash - beginning of period 48,615 60,146 48,615 60,896
Total cash and cash equivalents and restricted cash - end of period $ 46,664 $ 57,643 $ 45,286 $ 52,252

The composition of total cash and cash equivalents and restricted cash is as follows:
Cash and cash equivalents 45,914 56,893 $ 44,536 $ 51,502
Restricted cash included in other assets 750 750 750 750
Total cash and cash equivalents and restricted cash $ 46,664 $ 57,643 $ 45,286 $ 52,252

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
As of ~~October~~January 31, ~~2020~~2021
(Unaudited)
(Dollars in thousands, except share data)

Note 1 – Basis of Presentation

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics, Enzo Realty LLC and Enzo Realty II LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The Company has three reportable segments: Clinical Services, Products, and Therapeutics. The consolidated balance sheet as of ~~October~~January 31, ~~2020,~~2021, the consolidated statements of operations, comprehensive income (loss) and stockholders’ equity for the three and six months ended ~~October~~January 31, ~~2020,~~2021, and the consolidated statements of cash flows for the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2020 has been derived from the audited financial statements at that date. The results of operations for the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021.

A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers of our products closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors.

The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, spread and the emergence of variants, its treatment ~~including~~with authorized vaccines and vaccines in various stages of development and federal approval, and related work and travel advisories and restrictions, all of which are highly uncertain and cannot be reasonably predicted at this time. Global supply chain issues due to the pandemic hamper both ~~production~~the manufacturing of products within the life science division as well as testing capabilities in the clinical laboratory.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of ~~October~~January 31, ~~2020~~2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s patient self-pay revenue concessions and credit losses in the Clinical Services segment, accounts receivable, inventories and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.

Effect of New Accounting Pronouncements

Pronouncements Issued but Not Yet Adopted

In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326). This standard, as amended, changes the impairment model for most financial instruments, including trade receivables, from an incurred loss method to a new forward-looking approach, based on expected losses. The estimate of expected credit losses will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. Adoption of this standard is required for our annual and interim periods beginning August 1, 2023 as long as we continue to qualify as a smaller reporting company at the end of fiscal 2022, and must be adopted using a modified retrospective transition approach. We are currently assessing the impact of the adoption of this standard on our results of operations, financial position and cash flows.

In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The amendments in the ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this ASU are required for our annual and interim periods beginning August 1, 2021. The adoption of the amendments in this ASU is not expected to have a material impact on our consolidated results of operations, financial position or cash flows

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Concentration Risk

Other than the Medicare program, two providers whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately ~~33%~~35% and ~~28%~~34% of Clinical Services net revenue for the three ~~months~~and six month periods ended ~~October~~January 31, ~~2020 and 2019 respectively. As of October 31, 2020, the Medicare program represents~~2021. These two providers represent approximately ~~18%~~33% of Clinical Services net ~~receivables.~~revenue for each of the three and six month periods ended January 31, 2020

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected.

We maintain a full valuation allowance on all tax assets and, as a consequence, do not provide any tax benefit for the fiscal 2020 period loss or tax provision for the fiscal 2021 period pre-tax income.

Fair Value Measurements

The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market.

Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.
Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Note 2 – Net income (loss) per share

Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three and six months ended ~~October~~January 31, ~~2020,~~2021, approximately ~~10,000~~47,000 and 23,000 weighted average stock options respectively were included in the calculation of diluted weighted average shares outstanding. As a result of the net loss for the three and six months ended ~~October~~January 31, ~~2019,~~2020, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options, unearned performance stock units and unvested restricted stock because to do so would be antidilutive. For the three and six months ended ~~October~~January 31, ~~2019,~~2020, approximately ~~127,000~~zero and 64,000 of potential common shares (“in the money options”) and unvested restricted stock respectively, were excluded from the calculation of diluted earnings per share.

For the three and six months ended ~~October~~January 31, ~~2020 and 2019,~~2021, the effect of approximately ~~2,146,000~~2,264,000 and ~~1,319,000~~2,122,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and six months ended January 31, 2020, the effect of approximately 1,897,000 and 1,606,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Note 3 – Revenue Recognition

Clinical Services Revenue

Service revenues in the Company’s clinical services business accounted for approximately ~~73%~~75% and 64% of the Company’s total revenues for the ~~three~~six months ended ~~October~~January 31, 2021 and 2020, and are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratories and will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers, government payers, client payers and patients as described below. Contracts with customers in our laboratory services business do not contain a financing component, based on the typically limited period of time between performance of services and collection of consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessions as well as the collectability of the transaction based on patient intent and ability to pay. The Company uses the expected value method in estimating the amount of the variability included in the transaction price.

The following are descriptions of our laboratory services business portfolios:

Third party payers and Health Maintenance Organizations (HMO’s)

Reimbursements from third party payers, primarily healthcare insurers and HMO’s are based on negotiated fee-for-service schedules and on capitated payment rates. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement.

Collection of the consideration the Company expects to receive is normally a function of providing complete and correct billing information to these third party payers within the various filing deadlines, and typically occurs within 30 to 90 days of billing. Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, will reserve accordingly for the billing.

Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payers in interpretations, requirements, and “conditions of participation” in various programs.

Government Payer - Medicare

Reimbursements from Medicare are based on fee-for-service schedules set by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historical collection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement.

11

Collection of consideration the Company expects to receive is normally a function of providing the complete and correct billing information within the various filing deadlines and typically occurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordingly for the billing.

Patient self pay

Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based on fees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Patient responsibility is invoiced and if it reaches 91 days outstanding, the account is sent to a collection agency for further processing. After the account has been with the collection agency for at least 105 days, and is determined to be uncollectable it is written off.

The following table represents clinical services net revenues and percentages by type of customer:
Three months ended
January 31, 2021 Three months ended
January 31, 2020
Revenue category
Third-party payer $ 15,023 63 % $ 6,404 51 %
Medicare 3,910 16 3,025 24
Patient self-pay 1,997 8 1,447 12
HMO’s 3,058 13 1,637 13
Total $ 23,988 100 % $ 12,513 100 %

Three months ended
October 31, 2020 Three months ended
October 31, 2019 Six months ended
January 31, 2021 Six months ended
January 31, 2020
Revenue category
Third-party payer $ 13,539 64 % $ 6,392 50 % $ 27,503 61 % $ 12,796 51 %
Medicare 3,257 15 3,153 25 7,313 16 6,178 24
Patient self-pay 2,559 12 1,519 12 4,556 10 2,966 12
HMO’s 1,868 9 1,716 13 5,839 13 3,353 13
Total $ 21,223 100 % $ 12,780 100 % $ 45,211 100 % $ 25,293 100 %

For ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019,~~2020, all of the Company’s clinical services revenues were generated within the United States.

Products Revenue

Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products.

~~Products revenue by geography is as follows:~~
Products revenue by geography is as follows:
Three Months Ended
January 31

Six Months Ended
January 31

2021 2020 2021 2020
United States $ 3,524 $ 3,807 $ 7,469 $ 8,331
Europe 2,635 2,066 5,066 3,975
Asia Pacific 1,319 998 2,375 1,992
Products revenue $ 7,478 $ 6,871 $ 14,910 $ 14,298

Three Months Ended
October 31

2020 2019
United States $ 3,878 $ 4,447
Europe 2,382 1,865
Rest of the world 1,172 1,115
Products revenue $ 7,432 $ 7,427

Note 4 - Supplemental disclosure for statement of cash flows

In the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019,~~2020, interest paid by the Company was ~~$63~~$123 and ~~$69,~~$136, respectively.

For the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019,~~2020, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was ~~$24~~$48 and ~~$45,~~$91, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows.

~~For the three months ended October 31, 2020 and 2019, tax on capital paid by~~In January 2021, the Company ~~was $22 and $43, respectively.~~issued 332,700 shares of common stock to two senior executives in settlement of their accrued bonuses totaling $875.

Note 5 – Inventories

Inventories consist of the following at ~~October~~January 31:
October 31,
2020 July 31,
2020 January 31,
2021 July 31,
2020
Raw materials $ 1,320 $ 1,019 $ 1,266 $ 1,019
Work in process 2,603 2,587 2,561 2,587
Finished products 4,262 4,178 5,431 4,178
$ 8,185 $ 7,784 $ 9,258 $ 7,784

Note 6 – Goodwill and intangible assets

Goodwill

The Company’s net carrying amount of goodwill is in the Clinical Laboratory Services segment and is $7,452 as of ~~October~~January 31, ~~2020~~2021 and ~~2019.~~2020.

Intangible assets

The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences Products segment is as follows:
Gross Accumulated Amortization Net Gross Accumulated Amortization Net
July 31, 2020 $ 27,686 $ (27,148 ) $ 538 $ 27,686 $ (27,148 ) $ 538
Amortization expense — (75 ) (75 ) -   (151 ) (151 )
Foreign currency translation (64 ) 61 (3 ) 168 (162 ) 6
October 31, 2020 $ 27,622 $ (27,162 ) $ 460
January 31, 2021 $ 27,854 $ (27,461 ) $ 393

Intangible assets, all finite-lived, consist of the following:

October 31, 2020 July 31, 2020
Gross Accumulated
Amortization Net Gross Accumulated
Amortization Net
Patents $ 11,027 $ (11,019 ) $ 8 $ 11,027 (11,014 ) $ 13
Customer relationships 11,968 (11,516 ) 452 12,003 (11,478 ) 525
Website and acquired content 1,020 (1,020 ) — 1,022 (1,022 ) —
Licensed technology and other 481 (481 ) — 483 (483 ) —
Trademarks 3,126 (3,126 ) — 3,151 (3,151 ) —
Total $ 27,622 $ (27,162 ) $ 460 $ 27,686 (27,148 ) $ 538
~~At October 31, 2020, information with respect to acquired intangibles is as follows:~~
January 31, 2021 July 31, 2020
Gross Accumulated
Amortization Net Gross Accumulated
Amortization Net
Patents $ 11,027 $ (11,023 ) $ 4 $ 11,027 (11,014 ) $ 13
Customer relationships 12,095 (11,706 ) 389 12,003 (11,478 ) 525
Website and acquired content 1,028 (1,028 ) -   1,022 (1,022 ) -
Licensed technology and other 492 (492 ) -   483 (483 ) -
Trademarks 3,212 (3,212 ) -   3,151 (3,151 ) -
Total $ 27,854 $ (27,461 ) $ 393 $ 27,686 (27,148 ) $ 538

At January 31, 2021, information with respect to acquired intangibles is as follows:   Useful life assigned Weighted average
remaining useful life
Customer relationships 8 -15 years ~~2 years~~1 year

At ~~October~~January 31, ~~2020,~~2021, the weighted average remaining useful life of all intangible assets was approximately two years.

Note 7 – Long term debt

In connection with the purchase of our new facility in November 2018, a wholly-owned subsidiary (the “mortgagor subsidiary”) of the Company entered into a Fee Mortgage and Security Agreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement provides for a loan of $4,500 for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage payments of principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balance of unamortized debt issuance cost was ~~$59~~$57 at ~~October~~January 31, ~~2020.~~2021. At ~~October~~January 31, ~~2020,~~2021, the balance owed by the subsidiary under the mortgage agreement was $4.2 million. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of ~~October~~January 31, ~~2020.~~2021. We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020. Rental income from the assumed lease for the three and six months ended ~~October~~January 31, ~~2019~~2020 is included in ~~other~~Other income.

The mortgage agreement includes affirmative and negative covenants and events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgage includes certain financial and liquidity covenants. As of ~~October~~January 31, ~~2020,~~2021, the Company was in compliance with those covenants. The liquidity covenant requires that we own and maintain at all times and throughout the remaining term of the loan at least $25 million of liquid assets, defined as time deposits, money market accounts, commercial paper and obligations issued by the U.S. government or any of its agencies.

In April 2020, our subsidiary in Switzerland received a loan of CHF 0.4 million ($0.4 million, based on the foreign exchange rate as of ~~October~~January 31, ~~2020)~~2021) from the Swiss government under the “Corona Krise” emergency loan program in response to the pandemic. This loan is uncollateralized, bears 0% interest, is due in 5 years, and may be repaid at any time. This loan is included in long term debt – net as of ~~October~~January 31, ~~2020.~~2021.

The CARES Act expanded the U.S. Small Business Administration’s (SBA) business loan program to create the Paycheck Protection Program (PPP), which provides employers with uncollateralized loans whose primary purpose is to retain or maintain workforce and salaries for a twenty four week period (“covered period”) following receipt of the loan. Currently, PPP loans have a 1% fixed interest rate and are due from two to five years. The primary features of the PPP loan program are to provide funding to companies to cover eligible expenses, and the potential for forgiveness of that portion of the loan spent on payroll and other permitted operating expenses during the covered period, subject to reductions if the borrower fails to maintain or restore employee and salary levels. We applied for the PPP loan based on the eligibility and need requirements established when the program was announced and in April 2020 received $7,000 through Citibank N.A., the Company’s existing lender, pursuant to the PPP (the “PPP
Loan”).

The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty. No interest payments are due within the initial six months of the PPP Loan. Interest accrued during the initial six-month period is due and payable, together with the principal, on the Maturity Date. The Company used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments to support business continuity throughout the COVID-19 pandemic. All or a portion of the PPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptable documentation that demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’s requirements. Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditure eligibility, we did not recognize any loan forgiveness as of ~~October~~January 31, ~~2020~~2021 and have classified the loan as other short term debt as we expect to earn loan forgiveness on most, if not all of the loan in less than a ~~year.~~year, and have accrued no interest. The SBA intends to audit loans in excess of $2.0 million. The SBA also has announced its intention to require businesses that received loans in excess of $2 million to complete a loan necessity questionnaire to evaluate the good faith certification made on their PPP applications that economic uncertainty made their loan request necessary to support ongoing operations. No assurance can be given that we will obtain forgiveness of the PPP loan in whole or in part. We expect to apply for PPP loan forgiveness with the SBA through our intermediary lending bank in March 2021.

Minimum future annual principal payments under these agreements as of ~~October~~January 31, ~~2020~~2021 are as follows:
July 31, Total
2021 $ 7,074
2022 152
2023 160
2024 167
2025 604
Thereafter 3,476
Total principal payments 11,633
Less: current portion, included in other current liabilities and other short term debt (7,148 )
Unamortized mortgage cost (57 )
Long term debt - net $ 4,428

July 31, Total
2021 $ 7,109
2022 152
2023 160
2024 167
2025 595
Thereafter 3,471
Total principal payments 11,654
Less: current portion, included in other current liabilities and other short term debt (7,148 )
Unamortized mortgage cost (59 )
Long term debt - net $ 4,447

Note 8 - Leases

~~At the beginning of fiscal 2020, the~~The Company adopted ASU No. 2016-02 “Leases (Topic 842)”, which requires leases with durations greater than twelve months to be recognized on the balance ~~sheet. The Company adopted the standard~~sheet, using the modified retrospective approach ~~with an effective date~~as of August 1, 2019. ~~The Company did not apply the new standard to comparative periods and therefore those amounts are not presented below.~~

The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operating leases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate.

The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.), which have generally been combined and accounted for as a single lease component.

The Company’s leases have remaining terms of less than 1 year to 8 years, some of which include options to extend the leases for up to 5 years. The Company’s lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised.

Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities.
Leases Balance Sheet Classification October 31,
2020 Balance Sheet Classification January 31, 2021
Assets
Operating Right-of-use assets $ 19,316 Right-of-use assets $ 18,459
Finance Property, plant and equipment, net (a) 319 Property, plant and equipment, net (a) 286
Total lease assets $ 19,635 $ 18,745

Liabilities
Current:
Operating Current portion of operating lease liabilities $ 3,966 Current portion of operating lease liabilities $ 3,680
Finance Finance leases short term 109 Finance leases short term 66

Non-current:
Operating Operating lease liabilities, non-current 16,257 Operating lease liabilities, non-current 15,710
Finance Other liabilities and finance leases long term 173 Other liabilities and finance leases long term 155
Total lease liabilities $ 20,505 $ 19,611

(a) Accumulated amortization of finance lease assets was approximately ~~$1.0~~$1.1 million as of ~~October~~January 31, ~~2020.~~2021.

Components of lease cost were as follows:

Lease cost October 31,
2020
Three months ended
January 31, Six months ended
January 31,
2021 2020 2021 2020
Operating lease cost $ 1,479 $ 1,515 $ 1,474 $ 2,994 $ 2,948
Finance lease cost:
Amortization of leased assets 66 33 60 99 115
Interest on lease liabilities 5 4 22 9 34
Total lease cost $ 1,550 $ 1,552 $ 1,556 $ 3,102 $ 3,097

The maturity of the Company’s lease liabilities as of ~~October~~January 31, ~~2020~~2021 is as follows:
Maturity of lease liabilities, years ending July 31, Operating leases Finance leases Total Operating leases Finance leases Total
2021 $ 3,933 $ 87 $ 4,020 $ 2,436 $ 44 $ 2,480
2022 4,000 88 4,088 4,017 88 4,105
2023 3,305 88 3,393 3,318 88 3,406
2024 3,274 44 3,318 3,173 22 3,195
2025 3,275 — 3,275 3,145 — 3,145
Thereafter 6,402 — 6,402 6,370 — 6,370
Total lease payments 24,189 307 24,496 22,459 242 22,701
Less: Interest (a) 3,966 25 3,991 (3,069 ) (21 ) (3,090 )
Present value of lease liabilities $ 20,223 $ 282 $ 20,505 $ 19,390 $ 221 $ 19,611

(a) Primarily calculated using the Company’s incremental borrowing rate.

Lease term and discount rate for the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 were as follows:

Lease term and discount rate
Weighted-average remaining lease term (years):
Operating leases ~~6.1~~5.9 years
Finance leases 2.9 years

Weighted-average discount rate:
Operating leases ~~4.9~~4.95 %
Finance leases ~~9.1~~9.02 %

See Note 4 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the ~~three~~six months ended ~~October~~January 31, ~~2020.~~2021.

Note 9 – Accrued Liabilities

At ~~October~~January 31, accrued liabilities consist of:
January 31,
2021 July 31,
2020
Payroll, benefits, and commissions $ 5,601 $ 5,227
Professional fees 704 710
Legal 3,638 2,647
Deferred revenue – CARES Act Advance Payment 2,526 2,526
Other 2,120 1,723
$ 14,589 $ 12,833

October 31,
2020 July 31,
2020
Payroll, benefits, and commissions $ 5,390 $ 5,227
Professional fees 678 710
Legal 2,653 2,647
Deferred revenue – CARES Act Advance Payment 2,526 2,526
Other 3,266 1,723
$ 14,513 $ 12,833
Deferred revenue

In order to increase cash flow to providers of services and suppliers impacted by the pandemic, the Centers for Medicare and Medicaid Services (CMS) expanded its Accelerated and Advance Payment Program to a broader group of Medicare providers. We applied for and received a $2,526 payment advance from this program in April 2020. The recoupment by CMS of our advance payment had been scheduled to begin 120 days after the date of receipt, at which time every claim we submit from that point would be automatically offset to repay the advance payment. Any unrecouped advance balance remaining after 90 days of the recoupment process was to be repaid such that 210 days after receiving the advance it would be entirely repaid. In October 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act amended the repayment terms of the Advance Payment Program. The recoupment period was extended and the automatic recoupment will begin one year after the date the advance payment was received, which in our case means recoupment will start April 2021. During the first 11 months after recoupment begins, the rate will be 25% of claims processed and repayment will occur through an automatic recoupment of our Medicare payments. We expect the entire balance of the payment advance to be recouped by the end of the 11 month period. If the total amount of the advance payment is not recovered within 29 months from the date the advance was received, a demand letter for the outstanding balance will be issued. Since the Company has the right to repay the advance at any time, the entire balance is considered current.

Self-Insured Medical Plan

The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of ~~October~~January 31, ~~2020,~~2021, the Company has established a reserve of ~~$331,~~$349, which is included in accrued liabilities, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Note 10 – Stockholders’ Equity

Controlled Equity Offering

The Company has a Controlled Equity Offering^SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0 million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million.

In September 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.2 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 2017.

During the ~~three~~six months ended ~~October~~January 31, ~~2020~~2021 and ~~2019,~~2020, the Company did not sell any shares of Common Stock under the Sales Agreement.

Share-based compensation

In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) for the issuance of equity awards, including, among others, options, restricted stock and restricted stock units for up to 3,000,000 shares of common stock. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan (the “Amended and Restated 2011 Plan”) to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company’s Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company’s stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. In January 2021, the Company’s stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan.

The exercise price of options granted under the Amended and Restated 2011 Plan, as amended and restated, is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan, as amended and restated, will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan, as amended and restated, will remain in effect until they have been exercised or terminated, or have expired. As of ~~October~~January 31, ~~2020,~~2021, there were approximately ~~741,000~~4,623,000 shares of common stock available for grant under the Amended and Restated 2011 Plan, as amended and restated.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

Three months ended
October 31, Three months ended
January 31, Six months ended
January 31,
2020 2019 2021 2020 2021 2020
Stock options $ 166 218 $ 175 $ 301 $ 341 $ 518
Restricted stock 1 1 1 1 2 3
$ 167 219 $ 176 $ 302 $ 343 $ 521

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

Three months ended
October 31, Three months ended
January 31, Six months ended
January 31,
2020 2019 2021 2020 2021 2020
Selling, general and administrative $ 154 219 $ 162 $ 302 $ 316 $ 521
Cost of revenues 13 — 14 -   27 -
$ 167 219 $ 176 $ 302 $ 343 $ 521

No excess tax benefits were recognized during the ~~three~~six month periods ended ~~October~~January 31, ~~2020~~2021 and ~~2019.~~2020.
14

Stock Option Plans

The following table summarizes stock option activity during the ~~three~~six month period ended ~~October~~January 31, ~~2020:~~2021:

Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value (000s) Options Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value (000s)
Outstanding at July 31, 2020 2,636,496 $ 4.05 2,636,496 $ 4.05
Awarded 68,500 $ 2.14 543,104 $ 2.57
Exercised — $ — $
Cancelled or expired (52,000 ) $ 4.51
Expired or forfeited (408,539 ) $ 2.91
Outstanding at end of period 2,652,996 $ 3.86 2.75 years $ 23 2,771,061 $ 3.80 3.0 years $ 114
Exercisable at end of period 1,537,662 $      1.4 years $            1,566,259 $      1.9 years $

As of ~~October~~January 31, ~~2020,~~2021, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was ~~$751~~$1,079 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately ~~thirteen~~nineteen months.

The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options.

Performance Stock Units

To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the ~~Company granted~~Company’s board of directors approved long-term incentive awards in the form of ~~time based stock options and~~ performance-based ~~restricted~~ stock units (“Performance Stock Units” or “PSUs”). in addition to time based stock options. The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group.

During the fiscal years ended 2020, 2019 and 2018, the ~~Company awarded~~Company’s board of directors approved the award of PSUs to its executive ~~officers.~~officers, whose established grant dates are in the table below. These awards provide for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. During the ~~three~~six months ended ~~October~~January 31, 2021, one former executive forfeited a total of 6,000 PSUs. During the six months ended January 31, 2020, one former executive forfeited a total of ~~6,000~~14,500 PSUs. As of ~~October~~January 31, ~~2020,~~2021, the Company did not accrue any compensation expense for ~~these PSU’s as~~ the ~~achievement~~outstanding PSU’s. There were no PSU awards approved by the Company’s board of directors through the ~~growth goals is currently not probable.~~six months ended January 31, 2021.

The following table summarizes PSU’s granted and outstanding as of ~~October~~January 31, ~~2020:~~2021:
Grant Date Total Grant Forfeitures Outstanding
Fair Market Value
At Grant Date (000s)

10/15/2018 32,000 (6,000 ) 26,000 $ 107
10/15/2019 80,500 (14,500 ) 66,000 $ 222
10/19/2020 98,600 -   98,600 $ 207

Grant Date Total Grant Forfeitures Outstanding
Fair Market Value
At Grant Date (000s)

7/31/2018 32,000 (6,000 ) 26,000 $ 124
1/3/2019 80,500 (14,500 ) 66,000 $ 196
2/25/2020 98,600 — 98,600 $ 217

~~Restricted Stock Awards~~
The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2020, there were 817 shares of unvested restricted stock which have a weighted average award price of $3.34 per share. As of October 31, 2020, there was approximately $1 of unrecognized compensation cost related to these unvested shares of restricted stock to be recognized over a weighted average remaining period of approximately three months. There were no awards that were made or vested during the three months ended October 31, 2020 or 2019.
Note 11 – Segment reporting

The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The ~~Company’s~~Company��s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. All intersegment activities are eliminated.

Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to those segments.

Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2020 Clinical
Services Products Therapeutics Other Consolidated
Three months ended January 31, 2021 Clinical
Services Products Therapeutics Other Consolidated
Revenues – Services and Products $ 21,223 $ 7,432 — — $ 28,655 $ 23,988 $ 7,478 -   -   $ 31,466

Operating costs and expenses:
Cost of revenues 12,995 3,763 — — 16,758 11,708 3,937 -   -   15,645
Research and development 121 592 $ 33 — 746 160 633 $ 13 -   806
Selling, general and administrative 6,098 2,445 17 $ 1,454 10,014 6,425 2,593 16 $ 1,979 11,013
Legal and related expenses 25 5 — 610 640 71 1 -   2,220 2,292
Total operating costs and expenses 19,239 6,805 50 2,064 28,158 18,364 7,164 29 4,199 29,756

Operating income (loss) 1,984 627 (50 ) (2,064 ) 497 5,624 314 (29 ) (4,199 ) 1,710

Other income (expense):
Interest (6 ) 10 — (55 ) (51 ) (4 ) 8 -   (53 ) (49 )
Other 15 2 — — 17 14 2 -   -   16
Foreign exchange loss — (164 ) — — (164 )
Foreign exchange gain -   625 -   -   625
Net income (loss) $ 1,993 $ 475 $ (50 ) $ (2,119 ) $ 299 $ 5,634 $ 949 $ (29 ) $ (4,252 ) $ 2,302

Depreciation and amortization included above $ 409 $ 185 $ — $ 66 $ 660 $ 381 $ 188 $ -   $ 66 $ 635

Share-based compensation included in above:
Selling, general and administrative 9 16 — 129 154 10 16 -   136 162
Cost of revenues 13 — — — 13 14 -   -   -   14
Total $ 22 $ 16 $ — $ 129 $ 167 $ 24 $ 16 $ -   $ 136 $ 176

Capital expenditures $ 540 $ 44 $ — $ 33 $ 617 $ 341 $ 154 $ -   $ 11 $ 506

Three months ended October 31, 2019 Clinical
Services Products Therapeutics Other Consolidated
Three months ended January 31, 2020 Clinical
Services Products Therapeutics Other Consolidated
Revenues $ 12,780 $ 7,427 — — $ 20,207 $ 12,513 $ 6,871 -   -   $ 19,384
��
Operating costs and expenses:
Cost of revenues 10,975 3,546 — — 14,521 10,243 3,332 -   -   13,575
Research and development 350 516 188 — 1,054 373 503 189 -   1,065
Selling, general and administrative 6,215 2,757 — 2,167 11,139 5,895 2,530 -   2,268 10,693
Legal fee expense 50 — — 1,646 1,696 38 1 -   2,021 2,060
Total operating costs and expenses 17,590 6,819 188 3,813 28,410 16,549 6,366 189 4,289 27,393

Operating income (loss) (4,810 ) 608 (188 ) (3,813 ) (8,203 ) (4,036 ) 505 (189 ) (4,289 ) (8,009 )

Other income (expense):
Interest (12 ) 18 — 231 237 (10 ) 16 -   165 171
Other 3 (12 ) — 136 127 16 7 -   49 72
Foreign exchange loss — 191 — — 191
Foreign exchange gain -   79 -   -   79
Net (loss) income $ (4,819 ) 805 (188 ) (3,446 ) (7,648 ) $ (4,030 ) 607 (189 ) (4,075 ) (7,687 )

Depreciation and amortization included above $ 409 251 — 65 725 $ 392 253 -   65 710

Share-based compensation included in above:
Selling, general and administrative 34 22 — 163 219 33 22 -   247 302
Total $ 34 22 — 163 219 $ 33 22 -   247 302

Capital expenditures $ 147 127 — — 274 $ 142 18 -   -   160

Six months ended January 31, 2021 Clinical
Services Products Therapeutics Other Consolidated
Revenues – Services and Products $ 45,211 $ 14,910 -   -   $ 60,121

Operating costs and expenses:
Cost of revenues 24,703 7,700 -   -   32,403
Research and development 281 1,225 $ 46 -   1,552
Selling, general and administrative 12,523 5,038 33 $ 3,433 21,027
Legal and related expenses 96 6 -   2,830 2,932
Total operating costs and expenses 37,603 13,969 79 6,263 57,914

Operating income (loss) 7,608 941 (79 ) (6,263 ) 2,207

Other income (expense):
Interest (10 ) 18 -   (108 ) (100 )
Other 29 4 -   -   33
Foreign exchange gain 461 -   -   461
Net income (loss) $ 7,627 $ 1,424 $ (79 ) $ (6,371 ) $ 2,601

Depreciation and amortization included above $ 790 $ 373 $ -   $ 132 $ 1,295

Share-based compensation included in above:
Selling, general and administrative 19 32 -   265 316
Cost of revenues 27 -   -   -   27
Total $ 46 $ 32 $ -   $ 265 $ 343

Capital expenditures $ 881 $ 198 $ -   $ 44 $ 1,123

Six months ended January 31, 2020 Clinical
Services Products Therapeutics Other Consolidated
Revenues – Services and Products $ 25,293 $ 14,298 -   -   $ 39,591

Operating costs and expenses:
Cost of revenues 21,218 6,878 -   -   28,096
Research and development 723 1,019 $ 377 -   2,119
Selling, general and administrative 12,110 5,287 -   $ 4,435 21,832
Legal and related expenses 88 1 -   3,667 3,756
Total operating costs and expenses 34,139 13,185 377 8,102 55,803

Operating income (loss) (8,846 ) 1,113 (377 ) (8,102 ) (16,212 )

Other income (expense):
Interest (22 ) 34 -   396 408
Other 19 (5 ) -   185 199
Foreign exchange gain -   270 -   -   270
Net income (loss) $ (8,849 ) $ 1,412 $ (377 ) $ (7,521 ) $ (15,335 )

Depreciation and amortization included above $ 801 $ 503 $ -   $ 130 $ 1,434

Share-based compensation included in above:
Selling, general and administrative. 67 44 -   410 521
Total $ 67 $ 44 $ -   $ 410 $ 521

Capital expenditures $ 289 $ 145 $ -   $ -   $ 434

Note 12 Contingencies

The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ‘180 and ‘405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020. There are currently two cases that were originally brought by the Company in the Court. In those two cases, Enzo alleges patent infringement against Becton Dickinson Defendants and Roche Defendants, respectively. The claims in those cases involve the ‘197 Patent. Both cases are stayed.

In separate inter partes review proceedings before the U.S. Patent and Trademark Office involving, among others, Becton Dickinson, certain claims of the ‘197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which was denied.

In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ~~��180~~’180 and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the inter partes review proceedings regarding the ’197 Patent filed by Hologic and joined by Becton Dickinson mentioned above.

On February 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“Plaintiffs”) brought an action in the United States District Court for the Southern District of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer (“defendants”). On March 26, 2020, Plaintiffs filed an amended complaint against the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made two purportedly false statements: (a) a “January 28, 2020 Enzo press release [that purportedly] falsely stated that the Annual Meeting would be ‘delayed’ by action of the Board to February 25, 2020 when, in fact, the Annual Meeting would convene as planned on January 31, 2020”, and (b) a “January 31 Enzo Proxy [that purportedly] falsely stated that the Proposed By-Law Amendment [to Article II, Section 9] would be approved if it received…a majority of the votes….rather than the required Supermajority Vote as provided for in the Charter. ”Count II asserted a claim against the individual defendants under Section 20(a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Finally, Count IV purported to assert a derivative claim for a declaration that any amendment to Article II, Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the day before the defendant’s motion to dismiss was due, plaintiffs asked the Court to dismiss their claims without prejudice. Defendants asked plaintiffs to dismiss the claims with prejudice, but they refused. On July 17, 2020, the Court dismissed the claims without prejudice. If plaintiffs reassert the claims, defendants intend to vigorously defend against them.

On November 27, 2020, the Company brought an action in the United States District Court for the Southern District of New York against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp. and Kenan Lucas. The Company alleges the defendants made false and misleading representations, or omitted to state material facts necessary to make their statements not misleading, in proxy materials they disseminated seeking the election to the Company’s Board of Directors at its 2019 Annual Meeting of two candidates they nominated, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder. The Company seeks damages and injunctive relief. Defendants have ~~not yet responded~~filed a motion to ~~the complaint.~~dismiss. The Company has filed its opposition to that motion.

There can be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020, we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheld by the payer shall fully and completely satisfy the dispute.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information about our Company’s financial results and estimates, business prospects and products in research and development that involve substantial risks and uncertainties. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “will”, and other words and terms of similar meaning in connection with any discussion of future operations or financial performance.

In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, impacts of the COVID-19 pandemic and measures we have taken in response, and financial results. We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the July 31, 2020 fiscal ~~year and updated in Item 1A. “Risk Factors in this Form 10-Q,~~year. You are advised to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results.

You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Impact of COVID-19 pandemic

A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers of our products closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors.

Enzo was granted FDA Emergency Use Authorization (EUA) for its molecular diagnostic and serological testing for COVID-19 and related antibody testing options. Enzo’s innovations include virus-inactivating specimen collection media to lessen transmission risks for healthcare providers and clinical laboratory personnel, the development of more relevant positive controls for the tests, and improved sensitivity.

In the ~~fourth~~second quarter of our fiscal year ~~ended~~ending July 31, ~~2020,~~2021, while non-COVID-19 accessions did not return to prior year levels, we continued to see non-COVID-19 accession volume rebound. ~~Due to~~With the addition of COVID-19 testing, total accession volume for the fiscal ~~first~~second quarter ended ~~October~~January 31, ~~2020~~2021 exceeded accession volume in both the sequential or ~~fourth~~first fiscal quarter ended ~~July~~October 31, 2020 and the prior year fiscal ~~first~~second quarter ended ~~October~~January 31, ~~2019.~~2020. However, it is too early to determine the long term significance of the positive impact from increased testing and the Company’s proprietary product offerings on revenue, profitability and cash flow.

The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, spread and the emergence of variants, its treatment ~~including~~with authorized vaccines and vaccines in various stages of development and federal approval, and related work and travel advisories and restrictions, all of which are highly uncertain and cannot be reasonably predicted at this time. Global supply chain issues due to the pandemic hamper both ~~production~~the manufacturing of products within the life science division as well as testing capabilities in the clinical laboratory.

The Coronavirus Aid, Relief, and Economic Security Act (CARES Act)

In March 2020, in response to the COVID-19 pandemic, the CARES Act was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures. The CARES Act also includes a number of benefits that are applicable to us and other healthcare providers including, but not limited to:

●· Providing clinical laboratories a one-year reprieve from the Centers for Medicare and Medicaid Services (CMS) private payer prices reporting requirements under the Protecting Access to Medicare Act (“PAMA”) as well as a one-year delay of a reimbursement rate ~~reductions~~reduction of 15% for clinical laboratory services provided under Medicare that ~~were~~was scheduled to take place instarting January 1, 2021. Further revisions of the Medicare Clinical Laboratory Fee Schedule (CLFS) for calendar years after 2021 will be based on future surveys of private payer market rates. ~~Reimbursement~~Medicare and Medicaid reimbursement reduction ~~from~~for calendar years 2022-2024 is capped by PAMA at 15% ~~annually;~~annually, which we estimate could then negatively impact our annualized Medicare and Medicaid revenues by $2.4 million. In this regard, the American Clinical Laboratory Association (ACLA) has filed a federal civil action challenging the legal basis for the private payer data collection methodology CMS used to derive the data from which median prices were calculated. ACLA continues to work with Congress on potential legislative reform of PAMA, which if adopted could reduce the negative impact of PAMA as currently implemented by CMS. The long-term effect of these efforts on Medicare CLFS rates is not determinable

●· Appropriating $100 billion to health care providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic. In April 2020, we received from Medicare a CARES Act Relief Payment grant of approximately $750 from the initial tranche and in July 2020 we received a second grant of approximately ~~$750;~~$750.

●· Allocated $349 billion to small businesses as Payment Protection Program (PPP) loans through the Small Business Administration (SBA). In April 2020, we received approximately $7.0 million from the initial tranche of this ~~program;~~program.

●· Providing an advance on testing services payments which can be either paid back at any time or earned back starting one year from receipt. In April 2020 we applied for and received a Medicare advance payment of $2.5 ~~million;~~million.

●· Suspending Medicare sequestration from May 2020 to December 2020. We estimate that the suspension of Medicare sequestration ~~will result~~resulted in a small benefit to us in the form of higher reimbursement rates for diagnostic testing services performed on behalf of Medicare beneficiaries.

Overview

Enzo Biochem, Inc. (the “Company” “we”, “our” or “Enzo”) is an integrated diagnostics, clinical lab, and life sciences company focused on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable our customers to meet their clinical needs. Through a connection with the market, we provide advanced biotechnology solutions to the global community as affordable and flexible quality products and services. We develop, manufacture and sell our proprietary technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo’s structure and business strategy represent the culmination of years of extensive planning and work. The Company has the unique ability to offer low cost, high performance products and services for diagnostic testing, which ideally positions us to capitalize on the reimbursement pressures facing diagnostic labs. Our pioneering work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company to continue to play an important role in the rapidly growing molecular medicine marketplaces.

Enzo develops low cost diagnostic platform products and related services. Our platform development includes automation-compatible reagent systems and associated products for sample collection and processing through analysis. We develop affordable products and services to improve healthcare, one of the greatest challenges today. Enzo combines over 40 years of expertise in technology development with assay development capabilities and diagnostic testing services to create high performance, cost-effective, and open assay solutions. The ability to combine these assets in one company is unique. With our strong intellectual property portfolio integrated with assay development know-how, production, distribution, validation and services capabilities, we have enabled sustainable products and services for a market that is facing increasing pressure in costs and reimbursement

Enzo technology solutions and platforms and unique operational structure are designed to reduce overall healthcare costs for both government and private insurers. Our proprietary technology platforms reduces our customers’ need for multiple, specialized instruments, and offer a variety of high throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused on large and growing markets primarily in the areas of personalized medicine, women’s health, infectious diseases and genetic disorders.

In the course of our research and development activities, we have built a substantial portfolio of intellectual property assets, comprised of 495 issued patents worldwide and 71 pending patent applications, along with extensive enabling technologies and platforms.

Below are brief descriptions of each of our operating segments (See Note 11 in the Notes to Consolidated Financial Statements):

Enzo Clinical Services is a clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Company believes having a Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified and College of American Pathologists (“CAP”) accredited medical laboratory located in New York provides us the opportunity to more rapidly introduce cutting edge products and services to the clinical marketplace. Enzo Clinical Labs offers an extensive menu of molecular and other clinical laboratory tests and procedures used in patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. Our laboratory is equipped with state-of-the-art communication and connectivity solutions enabling the rapid transmission, analysis and interpretation of generated data. We operate a full service clinical laboratory in Farmingdale, New York, a network of over 30 patient service centers throughout New York, New Jersey and Connecticut, two free standing “STAT” or rapid response laboratories in New York City and Connecticut, an in-house logistics department, and an information technology department. Under our license in New York State, we are able to offer testing services to clinical laboratories and physicians nationwide.

The Clinical Laboratory Services reporting unit is impacted by various risk factors, including among others, reduced reimbursements from third party payers for testing performed and from recent health care legislation. Despite the growth we have experienced in previous years, there can be no assurance future growth can be achieved. The introduction of new molecular and esoteric tests is expected to increase our revenue per test and could offset impacts from the above factors. The Company anticipates improved profitability with increased service volume.

Enzo Products manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. Information regarding our technologies can be found in the “Core Technologies” section. We are internationally recognized and acknowledged as a leader in the development, manufacturing validation and commercialization of numerous products serving not only the clinical research market, but also the life sciences markets in the fields of cellular analysis and drug discovery, among others. Our operations are supported by global operations allowing for the efficient marketing and delivery of our products around the world.

Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. This focus has generated a clinical and preclinical pipeline, as well as more than 100 patents and patent applications. In December 2020, Enzo announced it will consider various avenues to unlock value in Enzo Therapeutics. Alternatives under consideration include a possible spin-off, sale, joint venture or licensing of its intellectual property.

Results of Operations
Three months ended ~~October~~January 31, ~~2020~~2021 compared to ~~October~~January 31, ~~2019~~2020
(in 000s)

Comparative Financial Data for the Three Months Ended ~~October~~January 31,

2020 2019 Favorable (Unfavorable) % Change 2021 2020 Favorable (Unfavorable) % Change

Revenues $ 28,655 $ 20,207 $ 8,448 42 $ 31,466 $ 19,384 $ 12,082 62

Operating costs and expenses:
Cost of revenues 16,758 14,521 (2,237 ) (15 ) 15,645 13,575 (2,070 ) (15 )
Research and development 746 1,054 308 29 806 1,065 259 24
Selling, general and administrative 10,014 11,139 1,125 10 11,013 10,693 (320 ) (3 )
Legal and related expenses 640 1,696 1,056 62 2,292 2,060 (232 ) (11 )
Total operating costs, expenses and legal settlements, net 28,158 28,410 252 1
Total operating costs and expenses 29,756 27,393 (2,363 ) (9 )

Operating income (loss) 497 (8,203 ) 8,700 ** 1,710 (8,009 ) 9,719 **

Other income (expense):
Interest (51 ) 237 (288 ) ** (49 ) 171 (220 ) **
Other 17 127 (110 ) (87 ) 16 72 (56 ) (78 )
Foreign currency (loss) gain (164 ) 191 (355 ) **
Foreign currency gain 625 79 546 **
Total other income 592 322 270 84

Net income (loss) $ 299 $ (7,648 ) $ 7,947 ** $ 2,302 $ (7,687 ) $ 9,989 **

Net income (loss) per common share:
Basic $ 0.01 $ (0.16 ) $ 0.05 $ (0.16 )
Diluted $ 0.01 $ (0.16 ) $ 0.05 $ (0.16 )
Weighted average common shares outstanding:
Basic 47,895 47,557 48,006 47,557
Diluted 47,905 47,557 48,053 47,557

** not meaningful

Consolidated Results:

The “2021 period” and the “2020 period” refer to the three months ended ~~October~~January 31, ~~2020~~2021 and ~~October~~January 31, ~~2019,~~2020, respectively, which represent the ~~first~~second quarters of the Company’s fiscal year ending July 31.
Impacts of COVID-19

In July 2020, Enzo was granted FDA Emergency Use Authorization (EUA) for its molecular diagnostic and serological testing for COVID-19 and related antibody testing options. Enzo’s innovations include virus-inactivating specimen collection media to lessen transmission risks for healthcare providers and clinical laboratory personnel, the development of more relevant positive controls for the tests, and improved sensitivity. In the fourth quarter of our fiscal year ended July 31, 2020, while accessions in our Clinical Services segment did not return to prior year levels, we continued to see accession volume rebound. In that fourth quarter we partnered with pharmacies and state universities across New York State to provide COVID-19 testing. ~~As a result,~~Due to the continuing effects of the pandemic, accession volume ~~including for COVID-19 for~~in the 2021 period exceeded accession volume in the sequential first fiscal ~~first~~ quarter ended October 31, 2020 ~~exceeded accession volume in both the sequential fourth fiscal quarter ended July 31, 2020~~ and the ~~prior year fiscal first quarter ended October 31, 2019. However,~~2020 period due to COVID-19 testing, offsetting reductions in non-COVID-19 accessions due to the restrictive effects of COVID-19. At this time it is too early to determine the long term significance of the positive impact from increased COVID-19 testing and the Company’s proprietary product offerings on revenue, profitability and cash flow.

Clinical Services revenues for the 2021 period were ~~$21.2~~$24.0 million compared to ~~$12.8~~$12.5 million in the 2020 period, an increase of ~~$8.4~~$11.5 million or ~~66%~~92% year-over-year. Due to COVID-19, diagnostic testing volume measured by the total number of accessions for all our testing services increased ~~49%~~66% period over period, resulting in the 2021 period’s revenue increase. COVID-19 testing services have higher reimbursement rates than our core testing resulting in an improvement in our overall liquidation rate for collections.

COVID-19 testing offset the impact of the period over period decline in core testing volume as a result of the restrictive effects of COVID-19. Estimated collection amounts are subject to the complexities and ambiguities of third party payer billing, reimbursement regulations and claims processing, as well as issues unique to Medicare and Medicaid programs, and require us to consider the potential for adjustments when estimating variable consideration in the recognition of revenue in the period that the related services are rendered. The ~~impact from the Protecting Access to Medicare Act (“PAMA”) continues to~~effect of PAMA directly negatively ~~impact~~impacted reimbursements from Medicare and ~~third party payers.~~Medicaid in the 2021 and 2020 periods by approximately $0.4 million and $0.3 million, respectively.

Product revenues were ~~$7.4~~$7.5 million in ~~both~~ the 2021 period and $6.9 million in the 2020 ~~periods.~~period, an increase of $0.6 million or 9%. The negative effect of COVID-19 related government policies intended to reduce the spread of the pandemic impacted our Products revenues in the U.S. markets more than in markets in the rest of the world. In the 2021 period, the revenue decline in the U.S. market was fully offset by an increase in revenues sourced from markets outside the U.S., due to their improvement in infections rates and a rebound in demand.

The cost of Clinical Services was ~~$13.0~~$11.7 million in the 2021 period and ~~$11.0~~$10.2 million in the 2020 period, an increase of ~~$2.0~~$1.5 million from increased COVID-19 testing volume. Utilizing our internal manufacturing capabilities we reduced some of our reliance on reagents sourced from third parties. The gross profit margin on Clinical Services revenues in the 2021 period was ~~39%~~51% versus ~~14%~~18% in the 2020 period. In the 2021 period, liquidation rate improvements and the high margin on COVID-19 testing offset the effect of reduced volumes of our genetics and core testing services.

The cost of Product revenues was ~~$3.8~~$3.9 million in the 2021 period and ~~$3.5~~$3.3 million in the 2020 period, an increase of ~~$0.3~~$0.6 million or 6%18%. The gross profit margin on Products was ~~49%~~47% in the 2021 period and 52% in the 2020 period, negatively impacted by a decline in the current period of higher margin sales in the U.S. market ~~from~~due to COVID-19.

Research and development expenses were ~~$0.7~~$0.8 million in the 2021 period and ~~$1.0~~$1.1 million in the 2020 period, a decrease of $0.3 million or ~~29%~~24%. The decrease is attributable primarily to the Clinical Services division, where many research and development resources were repurposed to testing services in the current period.

Selling, general and administrative expenses were ~~$10.0~~$11.0 million during the 2021 period versus ~~$11.1~~$10.7 million during the 2020 period, ~~a decrease~~an increase of ~~$1.1~~$0.3 million or ~~10%~~3%. The Clinical Services expense ~~decreased $0.1~~increased $0.5 million primarily due to higher sales commissions and other compensation paid primarily for higher revenues from COVID-19, partially offset by the impact of cost savings initiatives undertaken throughout our fiscal year that ended July 31, 2020. The Life Sciences Products expense ~~decreased $0.3~~increased $0.1 million due to ~~the impact of cost savings initiatives lower travel expenses, and amortization of intangibles.~~an increase in information technology costs. The Other segment decreased ~~$0.7~~$0.3 million primarily for lower self-insured healthcare benefit costs, compensation expense, and professional fees.

Legal and related expenses were ~~$0.6~~$2.3 million during the 2021 period compared to ~~$1.7~~$2.1 million in the 2020 period, ~~a decrease~~an increase of ~~$1.1~~$0.2 million or ~~62%~~11% year-over-year. InThere were contested proxy activities in both periods, but the ~~2020~~2021 period ~~we recorded $0.8 million in legal~~also included activities related to identifying and related expenses as a result of a settlement agreement and release with a third-party payer whereby the parties agreed that the $0.8 million previously withheld by the payer fully and completely satisfied the dispute. In addition, legal expense associated with other legal activity including costs associated with on-going litigation and contract disputes decreased $0.3 million dueappointing new directors to the ~~timing~~board and defending the Company in an action related to the board of ~~activities.~~directors.

Interest expense, net was $0.1 million in the 2021 period versus income, net of $0.2 million in the 2020 period and represents interest on cash and cash equivalents net of interest expense, primarily on a mortgage. During the 2021 period, the amount of investable cash was lower as were interest rates earned on deposits compared to the 2020 ~~period. Due~~period, due to the actions by the Federal Reserve to cut its target interest rates near zero in response to ~~COVID-19, we expect there will be substantially little, if any, interest earned on our cash and cash equivalents for the foreseeable future.~~COVID-19.

The foreign currency revaluation ~~loss~~gain recognized by the Life Sciences Products segment during the 2021 period was ~~$0.2~~$0.6 million compared to ~~a gain of $0.2~~$0.1 million in the 2020 period, an ~~unfavorable variance~~increase of ~~$0.4~~$0.5 million. The larger revaluation ~~loss~~gain was due to ~~the depreciation~~more significant appreciation of the British pound and Swiss franc versus the U.S. dollar as of the end of the 2021 period. The appreciation of the British pound ~~had appreciated~~versus the U.S. dollar was less significant as of the end of the 2020 period.

Results of Operations
Six months ended January 31, 2021 compared to January 31, 2020
(in 000s)
Comparative Financial Data for the Six Months Ended January 31,
2021 2020 Favorable (Unfavorable) % Change

Revenues $ 60,121 $ 39,591 $ 20,530 52

Operating costs and expenses:
Cost of revenues 32,403 28,096 (4,307 ) (15 )
Research and development 1,552 2,119 567 27
Selling, general and administrative 21,027 21,832 805 4
Legal and related expenses 2,932 3,756 824 22
Total operating costs and expenses 57,914 55,803 (2,111 ) (4 )

Operating income (loss) 2,207 (16,212 ) 18,419 **

Other income (expense):
Interest (100 ) 408 (508 ) **
Other 33 199 (166 ) (83 )
Foreign currency gain 461 270 191 71
Total other income 394 877 (483 ) (55 )

Net income (loss) $ 2,601 $ (15,335 ) $ 17,936 **

Net income (loss) per common share:
Basic $ 0.05 $ (0.32 )
Diluted $ 0.05 $ (0.32 )
Weighted average common shares outstanding:
Basic 47,895 47,557
Diluted 47,905 47,557
** not meaningful
Consolidated Results:
The “2021 period” and the “2020 period” refer to the six months ended January 31, 2021 and January 31, 2020, respectively, which represent the first two quarters of the Company’s fiscal year ending July 31.
Clinical Services revenues for the 2021 period were $45.2 million compared to $25.3 million in the 2020 period, an increase of $19.9 million or 79% year-over-year. Due to COVID-19, diagnostic testing volume measured by the total number of accessions for all our testing services increased 57% period over period, resulting in the 2021 period’s revenue increase. COVID-19 testing services have higher reimbursement rates than our core testing resulting in an improvement in our overall liquidation rate for collections. COVID-19 testing offset the impact of the period over period decline in genetics and core testing volume as a result of the restrictive effects of COVID-19. Estimated collection amounts are subject to the complexities and ambiguities of third party payer billing, reimbursement regulations and claims processing, as well as issues unique to Medicare and Medicaid programs, and require us to consider the potential for adjustments when estimating variable consideration in the recognition of revenue in the period that the related services are rendered. The effect of PAMA directly negatively impacted reimbursements from Medicare and Medicaid in the 2021 and 2020 periods by approximately $0.8 million and $0.7 million, respectively.
Product revenues were $14.9 million in the 2021 period and $14.3 million in the 2020 period, an increase of $0.6 million or 4%. The negative effect of COVID-19 related government policies intended to reduce the spread of the pandemic impacted our Products revenues in the U.S. markets more than in markets in the rest of the world. In the 2021 period, the revenue decline in the U.S. market was fully offset by an increase in revenues sourced from markets outside the U.S., due to their improvement in infections rates and a rebound in demand.

The cost of Clinical Services was $24.7 million in the 2021 period and $21.2 million in the 2020 period, an increase of $3.5 million from increased COVID-19 testing volume. Utilizing our internal manufacturing capabilities we reduced some of our reliance on reagents sourced from third parties. The gross profit margin on Clinical Services revenues in the 2021 period was 45% versus 16% in the 2020 period. In the 2021 period, liquidation rate improvements and the high margin on COVID-19 testing offset the effect of reduced volumes of our genetics and core testing services.
The cost of Product revenues was $7.7 million in the 2021 period and $6.9 million in the 2020 period, an increase of $0.8 million or 12%. The gross profit margin on Products was 48% in the 2021 period and 52% in the 2020 period, negatively impacted by a decline in the current period of higher margin sales in the U.S. market due to COVID-19.
Research and development expenses were $1.6 million in the 2021 period and $2.1 million in the 2020 period, a decrease of $0.5 million or 27%. The decrease is attributable primarily to the Clinical Services division, where many research and development resources were repurposed to testing services in the current period.
Selling, general and administrative expenses were $21.0 million during the 2021 period versus $21.8 million during the 2020 period, a decrease of $0.8 million or 4%. The Other segment decreased $1.0 million primarily for lower self-insured healthcare benefit costs, share based compensation expense, and professional fees. The Life Sciences Products expense decreased $0.2 million due to lower travel and other in person marketing expenses. The Clinical Services expense increased $0.4 million primarily due to higher sales commissions and other compensation paid primarily for higher revenues from COVID-19, partially offset by the impact of cost savings initiatives undertaken throughout our fiscal year that ended July 31, 2020.
Legal and related expenses were $2.9 million during the 2021 period compared to $3.7 million in the 2020 period, a decrease of $0.8 million or 22%. There were contested proxy activities in both periods, but we incurred legal expenses relating to the contested proxy throughout the 2020 period compared to only during the latter half of the 2021 period.
Interest expense, net was $0.1 million in the 2021 period versus interest income, net of $0.4 million in the 2020 period and represents interest on cash and cash equivalents net of interest expense, primarily on a mortgage. During the 2021 period, the amount of investable cash was lower as were interest rates earned on deposits compared to the 2020 period, due to the actions by the Federal Reserve to cut its target interest rates to near zero in response to COVID-19.
The foreign currency revaluation gain recognized by the Life Sciences Products segment during the 2021 period was $0.5 million compared to $0.3 million in the 2020 period, an increase of $0.2 million. The larger revaluation gain was due to more significant appreciation of the British pound and Swiss franc versus the U.S. dollar as of the end of the 2021 period. The appreciation of the British pound versus the U.S. dollar was less significant as of the end of the 2020 period.

Liquidity and Capital Resources

At ~~October~~January 31, ~~2020,~~2021, the Company had cash and cash equivalents of ~~$45.9~~$44.5 million of which $1.1 million was in foreign accounts, as compared to cash and cash equivalents of $47.9 million, of which $0.9 million was in foreign accounts at July 31, 2020. It is the Company’s current intent to permanently reinvest these foreign funds outside of the United States, and its current plans do not demonstrate a need to repatriate them to fund its United States operations. The Company had working capital of ~~$36.7~~$39.9 million at ~~October~~January 31, ~~2020,~~2021, an increase of ~~$0.7~~$3.9 million, compared to $36.0 million at July 31, 2020. The increase in working capital during the six months ended January 31, 20201 was primarily due to increases in current assets such as accounts receivable and inventories, partially offset by a decrease in cash, and ~~an increase~~a decrease in ~~accrued liabilities during the three months ended October 31, 2020.~~accounts payable.

Net cash used in operating activities during the fiscal 2021 period was approximately ~~$1.2~~$2.0 million as compared to ~~$2.1~~$8.0 million during the fiscal 2020 period, ~~a decrease~~an improvement of approximately ~~$0.9~~$6.0 million. The net cash used in the 2021 period was due primarily to ~~the~~ net income of ~~$0.3~~$2.6 million and non-cash expenses of approximately ~~$1.2~~$1.6 million which were more than offset by a net increase of ~~$2.7~~$6.2 million in operating assets and liabilities including, but not limited to, accounts receivable and inventories. The net cash used in the 2020 period was due primarily to a net loss of ~~$7.7 million and depreciation and amortization of $0.7~~$15.3 million partially offset by non-cash expenses of $2.0 million and a net decrease of ~~$4.6~~$5.3 million in operating assets and liabilities.

Net cash used in investing activities in fiscal 2021 was approximately ~~$0.6~~$1.1 million as compared to ~~$0.3~~$0.4 million in the 2020 period, an increase of ~~$0.3~~$0.7 million, all for ~~increases in~~ capital expenditures. Cash used in financing activities in both fiscal 2021 and fiscal 2020 was approximately ~~$0.1 million as compared to~~ $0.2 million ~~in fiscal 2020 and were~~ for payments related to a mortgage and finance leases.

As of ~~October~~January 31, ~~2020,~~2021, we have a $7.0 million loan from the Small Business Administration Paycheck Protection Program (PPP) ~~loan we~~ received during the fiscal year ended July 31, 2020. The PPP loan bears interest of 1% per annum. All or a portion of the PPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptable documentation that demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’s requirements. Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditure eligibility, we did not recognize any loan forgiveness as of ~~October~~January 31, ~~2020~~2021 and have classified the loan as other short term debt as we expect to earn loan forgiveness on most, if not all of the loan ~~in less than a~~during the current fiscal year. See Note 107 in the notes to consolidated financial statements.

As of ~~October~~January 31, ~~2020~~2021 we have a ~~long term~~ mortgage principal balance of ~~$4.0~~$4.2 million entered into for the purchase of a building facility, which bears a fixed interest rate of 5.09% per annum. It requires monthly mortgage payments of $30. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security, which is included in other assets as of ~~October~~January 31 ~~2020.~~2021. Effective October 19, 2020, the Company and the mortgagee ~~had~~ agreed to a covenant restructure whereby the mortgagee waived the Company’s financial ratio covenant for the fiscal period ended July 31, 2020 and modified the mortgage to replace that covenant with a liquidity covenant. The liquidity covenant requires that we own and maintain at all times, and throughout the remaining term of the loan, at least $25 million of liquid assets, defined as time deposits, money market accounts and commercial paper, and obligations issued by the U.S. government or any of its agencies. The cash collateral agreement was also modified to require compliance with the liquidity covenant for two consecutive fiscal years before the collateral is released back to us. As of ~~October~~January 31, ~~2020,~~2021, the Company was in compliance with financial and liquidity covenants related to this mortgage.

The Company believes that its current cash and cash equivalents level, and utilization of the Controlled Equity Offering program if necessary, as disclosed in Note 10 in the Notes to Consolidated Financial Statements are sufficient for its foreseeable liquidity and capital resource needs over at least the next twelve (12) months, although there can be no assurance that future events will not alter such view. Although there can be no assurances, in the event additional capital is required, the Company believes it has the ability to raise additional funds through equity offerings or other sources. Our liquidity plans are subject to a number of risks and uncertainties, including those described in the Item 1A. “Risk Factors” section of our Form 10-K for the year ended July 31, 2020, some of which are outside our control. Macroeconomic conditions could limit our ability to successfully execute our business plans and therefore adversely affect our liquidity plans.

Contractual Obligations

There have been no material changes to our Contractual Obligations as reported in our Form 10-K for the fiscal year ended July 31, 2020. Management is not aware of any material claims, disputes or settled matters concerning third party reimbursement that would have a material effect on our financial statements, except as disclosed in Note 12 to the Consolidated Financial Statements.

Off-Balance Sheet Arrangements

The Company does not have any “off-balance sheet arrangements” as such term is defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies

The Company’s discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.’s consolidated financial statements, certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted, as permitted under rules promulgated by the Security and Exchange Commission. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosure of contingent assets and liabilities.

On an on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for uncollectible accounts, inventory, operating lease liabilities, goodwill and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Revenues – Clinical Services

Contractual Adjustment

The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed.

Gross billings are based on a standard fee schedule we set for all third party payers, including Medicare, HMO’s and managed care. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors. The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company.

Our clinical business is primarily dependent upon reimbursement from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject to variances in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. We expect the efforts to impose reduced reimbursement, more stringent payment policies, and utilization and cost controls by government and other payers to continue. Changes that decrease reimbursement rates or coverage would negatively impact our revenues. The number of individuals covered under managed care contracts or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues from these programs.

During the three months ended ~~October~~January 31, ~~2020~~2021 and ~~2019,~~2020, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were ~~83.7%~~81.7% and ~~88.3%~~88.8%, respectively, of gross ~~billings.~~billings, respectively. InDuring the six months ended January 31, 2021 and 2020, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were 82.7% and 88.5%, respectively, of gross billings, respectively. The improvement in both periods is the result of COVID-19 testing reimbursements more closely matching our gross billing charges and fewer payer denials than what we experience for our core testing services .In general, the Company believes a decline in reimbursement rates or a shift to managed care or similar arrangements may be offset by the positive impact of an increase in the number of molecular tests we perform. However, there can be no assurance that we can increase the number of tests we perform or that if we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an increase in the number of tests we perform would result in increased revenue.

The Company estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could result in a change in clinical services revenues of approximately ~~$1.3~~$2.6 million and ~~$1.1~~$2.2 million for the ~~three~~six months periods ended ~~October~~January 31, ~~2020~~2021 and ~~2019~~2020 respectively, and a change in the net accounts receivable of approximately $0.7 million as of ~~October~~January 31, ~~2020.~~2021.

Our clinical services financial billing system records gross billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing. Therefore, we are unable to quantify the effect contractual adjustments recorded during the current period have on revenue recorded in a previous period. However, we can reasonably estimate our monthly contractual adjustment to revenue on a timely basis based on our quarterly review process, which includes:

● an analysis of industry reimbursement trends;

● an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;
● a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers; and

● an analysis of current gross billings and receivables by payer.
31

Government assistance grant income

Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenues are recognized when those expenses are incurred or during the period that the lost revenues is experienced, and are included in revenues.

Accounts Receivable

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.

The following is a table of the Company’s net accounts receivable by services and by products. Net receivables for Clinical Services are detailed by billing category and as a percent to its total net receivables. At ~~October~~January 31, ~~2020~~2021 and July 31, 2020, approximately 70% of the Company’s net accounts receivable relates to its Clinical Laboratory Services business, which operates in the New York, New Jersey and Connecticut medical communities.

The accounts receivable balance for Life Science products includes foreign receivables of $1.2 million or ~~33%~~32% and $1.0 million or 34% of its total receivables as of ~~October~~January 31, ~~2020~~2021 and July 31, 2020, respectively.

Net accounts receivable
Billing category As of
October 31, 2020 As of
July 31, 2020 As of
January 31, 2021 As of
July 31, 2020
Clinical Services
Third party payers $ 3,990 48 % $ 2,455 40 % $ 4,617 55 % $ 2,455 40 %
Patient self-pay 2,641 31 2,044 33 2,266 27 2,044 33
Medicare 1,551 18 884 14 1,482 17 884 14
HMO’s 233 3 797 13 50 1 797 13
Total Clinical Services 8,415 100 % 6,180 100 % 8,415 100 % 6,180 100 %
Total Life Sciences 3,636 2,961 3,680 2,961
Total accounts receivable – net $ 12,051 $ 9,141
Total accounts receivable - net $ 12,095 $ 9,141

The Company’s ability to collect outstanding receivables from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding.
The Company also assesses the current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment.

The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the accurate patient information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount. ~~As of October 31, 2020, approximately 18% of Clinical Labs receivables are from one payer.~~

Billing for clinical services is complicated because of many factors, especially: the differences between our standard gross fee schedule for all payers and the reimbursement rates of the various payers we deal with, disparity of coverage and information requirements among the various payers, and disputes with payers as to which party is responsible for reimbursement.

The following table indicates the Clinical Services aged gross receivables by payer group which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances not yet written off, and 3) other revenue adjustments.

As of October 31, 2020 Total % Third Party Payers % Medicare % Self-Pay % HMO’s %
As of January 31, 2021 Total % Third Party Payers % Medicare % Self-Pay % HMO’s %
1-30 days $ 22,293 35 $ 13,777 36 $ 3,956 30 $ 1,756 22 $ 2,804 68 $ 24,595 35 $ 16,655 35 $ 4,106 36 $ 1,671 21 $ 2,163 72
31-60 days 10,963 17 6,361 17 2,102 16 1,773 22 727 18 8,106 12 5,475 11 949 8 1,474 19 208 7
61-90 days 7,582 12 4,616 12 1,289 10 1,430 18 247 6 5,786 8 3,725 8 831 7 1,159 15 71 2
91-120 days 5,897 9 3,343 9 1,183 9 1,122 14 249 6 6,068 9 3,889 8 874 8 1,149 15 156 5
121-150 days 4,283 7 2,587 7 890 7 757 9 49 1 6,164 9 4,103 9 1,097 10 804 10 160 5
Greater than 150 days 12,149 19 7,239 19 3,719 28 1,170 15 21 1 19,594 28 14,320 30 3,482 31 1,549 20 243 8
Totals $ 63,167 100 % $ 37,923 100 % $ 13,139 100 % $ 8,008 100 % $ 4,097 100 % $ 70,313 100 % $ 48,167 100 % $ 11,339 100 % $ 7,806 100 % $ 3,001 100 %

As of July 31, 2020 Total % Third Party Payers % Medicare % Self-Pay % HMO’s %
1-30 days $ 21,074 44 $ 13,620 46 $ 3,897 42 $ 1,769 27 $ 1,788 94
31-60 days 7,080 15 4,588 15 1,081 12 1,307 20 104 5
61-90 days 3,616 8 2,358 9 618 7 632 10 8 1
91-120 days 1,474 3 940 3 243 3 284 4 7 —
121-150 days 2,614 6 1,594 5 367 4 649 10 4 —
Greater than 150 days 11,506 24 6,518 22 3,051 32 1,936 29 1 —
Totals $ 47,364 100 % $ 29,618 100 % $ 9,257 100 % $ 6,577 100 % $ 1,912 100 %

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected.

Inventory

The Company values inventory at the lower of cost (first-in, first-out) or net realizable value, which approximates market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

Leases - right of use assets and operating lease liabilities

The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operating leases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate. The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.,) which have generally been combined and accounted for as a single lease component.

On at least an annual basis, we perform a review of our business to determine if events or changes in circumstances have occurred that indicate that it is more likely than not that the carrying amount of an asset group, including long lived assets such as right of use assets, is not recoverable. If such events or changes in circumstances were deemed to have occurred, we would perform an impairment test of such long lived assets and record any noted impairment loss. Should the impact of the COVID-19 pandemic become significantly worse than currently expected, it is possible that we could incur impairment charges on long lived assets in the future.

Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. The Company tests goodwill and long-lived assets annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and long-lived assets for impairment, the Company has the option to perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is not required to perform a quantitative test in assessing goodwill and long-lived assets for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it identifies the reporting units and compares the fair value of each of these reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less than its fair value, no impairment exists. If the carrying amount of the reporting unit is higher than its fair value, the impairment charge is the amount by which the carrying amount exceeds its fair value, not to exceed the total amount of goodwill and intangibles allocated to the reporting unit.

On at least an annual basis, we perform a review of our business to determine if events or changes in circumstances have occurred that indicate that it is more likely than not that the fair value of a reporting unit with goodwill is less than its carrying value. If such events or changes in circumstances were deemed to have occurred, we would perform an impairment test of goodwill and record any noted impairment loss. Should the impact of the COVID-19 pandemic become significantly worse than currently expected, it is possible that we could incur impairment charges in the future.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in foreign currency exchange rates resulting from acquisitions with foreign locations (See Item 1A. Risk Factors section of the Form 10-K for the fiscal year ended July 31, 2020) that could impact our results of operations and financial position. We do not currently engage in any hedging or market risk management tools.

Foreign Currency Exchange Rate Risk

The financial reporting of our non-U.S. subsidiaries is denominated in currencies other than the U.S. dollar. Since the functional currency of our non-U.S. subsidiaries is the local currency, foreign currency translation adjustments are accumulated as a component of accumulated other comprehensive income in stockholders’ equity. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies at ~~October~~January 31, ~~2020,~~2021, our assets and liabilities would decrease by $0.4 million and $0.1 million, respectively, and our net sales and net earnings (loss) would decrease by $1.0 million and $0.1 million, respectively, on an annual basis.

We also maintain intercompany balances and loans with subsidiaries in different local currencies. These amounts are at risk of foreign exchange losses if exchange rates fluctuate. Assuming a hypothetical increase of 10% in the value of the U.S. dollar versus foreign currencies, our pre-tax earnings (loss) would be unfavorably impacted by approximately $1.7 million on an annual basis.

Interest Rate Risk

As of ~~October~~January 31, ~~2020,~~2021, we have fixed interest rate financing on a building mortgage, equipment finance leases, and the PPP loan from the SBA.

28

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of the Company’s “disclosure controls and procedures” (as such term is defined under the Exchange Act), under the supervision and with the participation of the principal executive officer and the principal financial officer. Based on this evaluation, the principal executive officer and the principal financial officer concluded that the Company’s disclosure controls and procedures are effective as of the end of the period covered by this report. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that it will detect or uncover failures within the Company to disclose material information otherwise required to be set forth in the Company’s periodic reports.

(b) Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended ~~October~~January 31, ~~2020~~2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION
~~Item 1.Legal Proceedings~~
Item 1. Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K for the fiscal year ended July 31, 2020 filed with the Securities and Exchange Commission, other than as noted in Note 12 to ~~the~~these Consolidated Financial Statements as of ~~October~~January 31, ~~2020.~~2021.
~~Item 1A.Risk Factors~~
Item 1A. Risk Factors

There has been no material changes from the risk factors disclosed in Part 1, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2020.
~~Item 6.Exhibits~~
Item 6. Exhibits

Exhibit No. Exhibit

31.1 Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of David Bench pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of David Bench pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101. INS* XBRL Instance Document

101. SCH* XBRL Taxonomy Extension Schema Document

101. CAL* XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* 101. DEF* XBRL Taxonomy Extension Definitions Linkbase Document

101.LAB* 101. LAB* XBRL Taxonomy Extension Label Linkbase Document

101.PRE* 101. PRE* XBRL Taxonomy Extension Presentation Linkbase Document

*XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENZO BIOCHEM, INC.
(Registrant)

Date: ~~December 11, 2020~~March 16, 2021 by: /s/ David Bench

Chief Financial Officer and
Principal Accounting Officer

31

	Common Stock Shares Issued		Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income		Total Stockholders’ Equity
Balance at July 31, 2020		47,895,050	$	479	$	334,473	$	(278,252	)	$	1,681	$	58,381
Net income for the period ended October 31, 2020		—		—		—		299			—		299
Share-based compensation charges		—		—		167		—			—		167
Foreign currency translation adjustments		—		—		—		—			171		171
Balance at October 31, 2020		47,895,050	$	479	$	334,640	$	(277,953	)	$	1,852	$	59,018

	Three months ended January 31, 2021				Three months ended January 31, 2020
Revenue category
Third-party payer	$	15,023	63	%	$	6,404	51	%
Medicare		3,910	16			3,025	24
Patient self-pay		1,997	8			1,447	12
HMO’s		3,058	13			1,637	13
Total	$	23,988	100	%	$	12,513	100	%

	Three months ended October 31, 2020				Three months ended October 31, 2019				Six months ended January 31, 2021				Six months ended January 31, 2020
Revenue category
Third-party payer	$	13,539	64	%	$	6,392	50	%	$	27,503	61	%	$	12,796	51	%
Medicare		3,257	15			3,153	25			7,313	16			6,178	24
Patient self-pay		2,559	12			1,519	12			4,556	10			2,966	12
HMO’s		1,868	9			1,716	13			5,839	13			3,353	13
Total	$	21,223	100	%	$	12,780	100	%	$	45,211	100	%	$	25,293	100	%

Products revenue by geography is as follows:	Three Months Ended January 31				Six Months Ended January 31
	2021		2020		2021		2020
United States	$	3,524	$	3,807	$	7,469	$	8,331
Europe		2,635		2,066		5,066		3,975
Asia Pacific		1,319		998		2,375		1,992
Products revenue	$	7,478	$	6,871	$	14,910	$	14,298

	Three Months Ended October 31
	2020		2019
United States	$	3,878	$	4,447
Europe		2,382		1,865
Rest of the world		1,172		1,115
Products revenue	$	7,432	$	7,427

	October 31, 2020		July 31, 2020		January 31, 2021		July 31, 2020
Raw materials	$	1,320	$	1,019	$	1,266	$	1,019
Work in process		2,603		2,587		2,561		2,587
Finished products		4,262		4,178		5,431		4,178
	$	8,185	$	7,784	$	9,258	$	7,784

	Gross			Accumulated Amortization			Net			Gross		Accumulated Amortization			Net
July 31, 2020	$	27,686		$	(27,148	)	$	538		$	27,686	$	(27,148	)	$	538
Amortization expense		—			(75	)		(75	)		-		(151	)		(151	)
Foreign currency translation		(64	)		61			(3	)		168		(162	)		6
October 31, 2020	$	27,622		$	(27,162	)	$	460
January 31, 2021										$	27,854	$	(27,461	)	$	393

At January 31, 2021, information with respect to acquired intangibles is as follows:		Useful life assigned		Weighted average remaining useful life
Customer relationships		8 -15 years		~~2 years~~1 year

July 31,	Total
2021	$	7,074
2022		152
2023		160
2024		167
2025		604
Thereafter		3,476
Total principal payments		11,633
Less: current portion, included in other current liabilities and other short term debt		(7,148	)
Unamortized mortgage cost		(57	)
Long term debt - net	$	4,428

Leases	Balance Sheet Classification	October 31, 2020		Balance Sheet Classification	January 31, 2021
Assets
Operating	Right-of-use assets	$	19,316	Right-of-use assets	$	18,459
Finance	Property, plant and equipment, net (a)		319	Property, plant and equipment, net (a)		286
Total lease assets		$	19,635		$	18,745

Liabilities
Current:
Operating	Current portion of operating lease liabilities	$	3,966	Current portion of operating lease liabilities	$	3,680
Finance	Finance leases short term		109	Finance leases short term		66

Non-current:
Operating	Operating lease liabilities, non-current		16,257	Operating lease liabilities, non-current		15,710
Finance	Other liabilities and finance leases long term		173	Other liabilities and finance leases long term		155
Total lease liabilities		$	20,505		$	19,611

Lease cost	October 31, 2020
			Three months ended January 31,				Six months ended January 31,
			2021		2020		2021		2020
Operating lease cost	$	1,479	$	1,515	$	1,474	$	2,994	$	2,948
Finance lease cost:
Amortization of leased assets		66		33		60		99		115
Interest on lease liabilities		5		4		22		9		34
Total lease cost	$	1,550	$	1,552	$	1,556	$	3,102	$	3,097

Maturity of lease liabilities, years ending July 31,	Operating leases		Finance leases		Total		Operating leases			Finance leases			Total
2021	$	3,933	$	87	$	4,020	$	2,436		$	44		$	2,480
2022		4,000		88		4,088		4,017			88			4,105
2023		3,305		88		3,393		3,318			88			3,406
2024		3,274		44		3,318		3,173			22			3,195
2025		3,275		—		3,275		3,145			—			3,145
Thereafter		6,402		—		6,402		6,370			—			6,370
Total lease payments		24,189		307		24,496		22,459			242			22,701
Less: Interest (a)		3,966		25		3,991		(3,069	)		(21	)		(3,090	)
Present value of lease liabilities	$	20,223	$	282	$	20,505	$	19,390		$	221		$	19,611

Lease term and discount rate
Weighted-average remaining lease term (years):
Operating leases	~~6.1~~5.9 years
Finance leases	2.9 years

Weighted-average discount rate:
Operating leases	~~4.9~~4.95	%
Finance leases	~~9.1~~9.02	%

	January 31, 2021		July 31, 2020
Payroll, benefits, and commissions	$	5,601	$	5,227
Professional fees		704		710
Legal		3,638		2,647
Deferred revenue – CARES Act Advance Payment		2,526		2,526
Other		2,120		1,723
	$	14,589	$	12,833

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)		Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2020		2,636,496		$	4.05						2,636,496		$	4.05
Awarded		68,500		$	2.14						543,104		$	2.57
Exercised		—						$			—						$
Cancelled or expired		(52,000	)	$	4.51
Expired or forfeited											(408,539	)	$	2.91
Outstanding at end of period		2,652,996		$	3.86		2.75 years	$	23		2,771,061		$	3.80		3.0 years	$	114
Exercisable at end of period		1,537,662		$			1.4 years	$			1,566,259		$			1.9 years	$

Grant Date	Total Grant		Forfeitures			Outstanding		Fair Market Value At Grant Date (000s)
10/15/2018		32,000		(6,000	)		26,000	$	107
10/15/2019		80,500		(14,500	)		66,000	$	222
10/19/2020		98,600		-			98,600	$	207

Grant Date	Total Grant		Forfeitures			Outstanding		Fair Market Value At Grant Date (000s)
7/31/2018		32,000		(6,000	)		26,000	$	124
1/3/2019		80,500		(14,500	)		66,000	$	196
2/25/2020		98,600		—			98,600	$	217

Three months ended October 31, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Three months ended January 31, 2021																Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	21,223		$	7,432			—			—		$	28,655		$	23,988		$	7,478		-			-		$	31,466

Operating costs and expenses:
Cost of revenues		12,995			3,763			—			—			16,758			11,708			3,937		-			-			15,645
Research and development		121			592		$	33			—			746			160			633	$	13			-			806
Selling, general and administrative		6,098			2,445			17		$	1,454			10,014			6,425			2,593		16		$	1,979			11,013
Legal and related expenses		25			5			—			610			640			71			1		-			2,220			2,292
Total operating costs and expenses		19,239			6,805			50			2,064			28,158			18,364			7,164		29			4,199			29,756

Operating income (loss)		1,984			627			(50	)		(2,064	)		497			5,624			314		(29	)		(4,199	)		1,710

Other income (expense):
Interest		(6	)		10			—			(55	)		(51	)		(4	)		8		-			(53	)		(49	)
Other		15			2			—			—			17			14			2		-			-			16
Foreign exchange loss		—			(164	)		—			—			(164	)
Foreign exchange gain																	-			625		-			-			625
Net income (loss)	$	1,993		$	475		$	(50	)	$	(2,119	)	$	299		$	5,634		$	949	$	(29	)	$	(4,252	)	$	2,302

Depreciation and amortization included above	$	409		$	185		$	—		$	66		$	660		$	381		$	188	$	-		$	66		$	635

Share-based compensation included in above:
Selling, general and administrative		9			16			—			129			154			10			16		-			136			162
Cost of revenues		13			—			—			—			13			14			-		-			-			14
Total	$	22		$	16		$	—		$	129		$	167		$	24		$	16	$	-		$	136		$	176

Capital expenditures	$	540		$	44		$	—		$	33		$	617		$	341		$	154	$	-		$	11		$	506

Three months ended October 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Three months ended January 31, 2020																Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	12,780		$	7,427			—			—		$	20,207		$	12,513		$	6,871		-			-		$	19,384
																										��
Operating costs and expenses:
Cost of revenues		10,975			3,546			—			—			14,521			10,243			3,332		-			-			13,575
Research and development		350			516			188			—			1,054			373			503		189			-			1,065
Selling, general and administrative		6,215			2,757			—			2,167			11,139			5,895			2,530		-			2,268			10,693
Legal fee expense		50			—			—			1,646			1,696			38			1		-			2,021			2,060
Total operating costs and expenses		17,590			6,819			188			3,813			28,410			16,549			6,366		189			4,289			27,393

Operating income (loss)		(4,810	)		608			(188	)		(3,813	)		(8,203	)		(4,036	)		505		(189	)		(4,289	)		(8,009	)

Other income (expense):
Interest		(12	)		18			—			231			237			(10	)		16		-			165			171
Other		3			(12	)		—			136			127			16			7		-			49			72
Foreign exchange loss		—			191			—			—			191
Foreign exchange gain																	-			79		-			-			79
Net (loss) income	$	(4,819	)		805			(188	)		(3,446	)		(7,648	)	$	(4,030	)		607		(189	)		(4,075	)		(7,687	)

Depreciation and amortization included above	$	409			251			—			65			725		$	392			253		-			65			710

Share-based compensation included in above:
Selling, general and administrative		34			22			—			163			219			33			22		-			247			302
Total	$	34			22			—			163			219		$	33			22		-			247			302

Capital expenditures	$	147			127			—			—			274		$	142			18		-			-			160

Six months ended January 31, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	45,211		$	14,910		-			-		$	60,121

Operating costs and expenses:
Cost of revenues		24,703			7,700		-			-			32,403
Research and development		281			1,225	$	46			-			1,552
Selling, general and administrative		12,523			5,038		33		$	3,433			21,027
Legal and related expenses		96			6		-			2,830			2,932
Total operating costs and expenses		37,603			13,969		79			6,263			57,914

Operating income (loss)		7,608			941		(79	)		(6,263	)		2,207

Other income (expense):
Interest		(10	)		18		-			(108	)		(100	)
Other		29			4		-			-			33
Foreign exchange gain					461		-			-			461
Net income (loss)	$	7,627		$	1,424	$	(79	)	$	(6,371	)	$	2,601

Depreciation and amortization included above	$	790		$	373	$	-		$	132		$	1,295

Share-based compensation included in above:
Selling, general and administrative		19			32		-			265			316
Cost of revenues		27			-		-			-			27
Total	$	46		$	32	$	-		$	265		$	343

Capital expenditures	$	881		$	198	$	-		$	44		$	1,123

Six months ended January 31, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	25,293		$	14,298			-			-		$	39,591

Operating costs and expenses:
Cost of revenues		21,218			6,878			-			-			28,096
Research and development		723			1,019		$	377			-			2,119
Selling, general and administrative		12,110			5,287			-		$	4,435			21,832
Legal and related expenses		88			1			-			3,667			3,756
Total operating costs and expenses		34,139			13,185			377			8,102			55,803

Operating income (loss)		(8,846	)		1,113			(377	)		(8,102	)		(16,212	)

Other income (expense):
Interest		(22	)		34			-			396			408
Other		19			(5	)		-			185			199
Foreign exchange gain		-			270			-			-			270
Net income (loss)	$	(8,849	)	$	1,412		$	(377	)	$	(7,521	)	$	(15,335	)

Depreciation and amortization included above	$	801		$	503		$	-		$	130		$	1,434

Share-based compensation included in above:
Selling, general and administrative.		67			44			-			410			521
Total	$	67		$	44		$	-		$	410		$	521

Capital expenditures	$	289		$	145		$	-		$	-		$	434

	2020			2019			Favorable (Unfavorable)			% Change			2021			2020			Favorable (Unfavorable)			% Change

Revenues	$	28,655		$	20,207		$	8,448			42		$	31,466		$	19,384		$	12,082			62

Operating costs and expenses:
Cost of revenues		16,758			14,521			(2,237	)		(15	)		15,645			13,575			(2,070	)		(15	)
Research and development		746			1,054			308			29			806			1,065			259			24
Selling, general and administrative		10,014			11,139			1,125			10			11,013			10,693			(320	)		(3	)
Legal and related expenses		640			1,696			1,056			62			2,292			2,060			(232	)		(11	)
Total operating costs, expenses and legal settlements, net		28,158			28,410			252			1
Total operating costs and expenses														29,756			27,393			(2,363	)		(9	)

Operating income (loss)		497			(8,203	)		8,700			**			1,710			(8,009	)		9,719			**

Other income (expense):
Interest		(51	)		237			(288	)		**			(49	)		171			(220	)		**
Other		17			127			(110	)		(87	)		16			72			(56	)		(78	)
Foreign currency (loss) gain		(164	)		191			(355	)		**
Foreign currency gain														625			79			546			**
Total other income														592			322			270			84

Net income (loss)	$	299		$	(7,648	)	$	7,947			**		$	2,302		$	(7,687	)	$	9,989			**

Net income (loss) per common share:
Basic	$	0.01		$	(0.16	)							$	0.05		$	(0.16	)
Diluted	$	0.01		$	(0.16	)							$	0.05		$	(0.16	)
Weighted average common shares outstanding:
Basic		47,895			47,557									48,006			47,557
Diluted		47,905			47,557									48,053			47,557


	●	a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers; and

Billing category	As of October 31, 2020				As of July 31, 2020				As of January 31, 2021				As of July 31, 2020
Clinical Services
Third party payers	$	3,990	48	%	$	2,455	40	%	$	4,617	55	%	$	2,455	40	%
Patient self-pay		2,641	31			2,044	33			2,266	27			2,044	33
Medicare		1,551	18			884	14			1,482	17			884	14
HMO’s		233	3			797	13			50	1			797	13
Total Clinical Services		8,415	100	%		6,180	100	%		8,415	100	%		6,180	100	%
Total Life Sciences		3,636				2,961				3,680				2,961
Total accounts receivable – net	$	12,051			$	9,141
Total accounts receivable - net									$	12,095			$	9,141

As of October 31, 2020	Total		%			Third Party Payers		%			Medicare		%			Self-Pay		%			HMO’s		%
As of January 31, 2021																										Total		%			Third Party Payers		%			Medicare		%			Self-Pay		%			HMO’s		%
1-30 days	$	22,293		35		$	13,777		36		$	3,956		30		$	1,756		22		$	2,804		68		$	24,595		35		$	16,655		35		$	4,106		36		$	1,671		21		$	2,163		72
31-60 days		10,963		17			6,361		17			2,102		16			1,773		22			727		18			8,106		12			5,475		11			949		8			1,474		19			208		7
61-90 days		7,582		12			4,616		12			1,289		10			1,430		18			247		6			5,786		8			3,725		8			831		7			1,159		15			71		2
91-120 days		5,897		9			3,343		9			1,183		9			1,122		14			249		6			6,068		9			3,889		8			874		8			1,149		15			156		5
121-150 days		4,283		7			2,587		7			890		7			757		9			49		1			6,164		9			4,103		9			1,097		10			804		10			160		5
Greater than 150 days		12,149		19			7,239		19			3,719		28			1,170		15			21		1			19,594		28			14,320		30			3,482		31			1,549		20			243		8
Totals	$	63,167		100	%	$	37,923		100	%	$	13,139		100	%	$	8,008		100	%	$	4,097		100	%	$	70,313		100	%	$	48,167		100	%	$	11,339		100	%	$	7,806		100	%	$	3,001		100	%

As of July 31, 2020	Total		%			Third Party Payers		%			Medicare		%			Self-Pay		%			HMO’s		%
1-30 days	$	21,074		44		$	13,620		46		$	3,897		42		$	1,769		27		$	1,788		94
31-60 days		7,080		15			4,588		15			1,081		12			1,307		20			104		5
61-90 days		3,616		8			2,358		9			618		7			632		10			8		1
91-120 days		1,474		3			940		3			243		3			284		4			7		—
121-150 days		2,614		6			1,594		5			367		4			649		10			4		—
Greater than 150 days		11,506		24			6,518		22			3,051		32			1,936		29			1		—
Totals	$	47,364		100	%	$	29,618		100	%	$	9,257		100	%	$	6,577		100	%	$	1,912		100	%

Exhibit No.		Exhibit

	31.1	Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	31.2	Certification of David Bench pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	32.1	Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	32.2	Certification of David Bench pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101. INS*	XBRL Instance Document

	101. SCH*	XBRL Taxonomy Extension Schema Document

	101. CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*	101. DEF*	XBRL Taxonomy Extension Definitions Linkbase Document

101.LAB*	101. LAB*	XBRL Taxonomy Extension Label Linkbase Document

101.PRE*	101. PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

	ENZO BIOCHEM, INC.
	(Registrant)

Date: ~~December 11, 2020~~March 16, 2021	by:	/s/ David Bench
		Chief Financial Officer and Principal Accounting Officer